Skip to content

KLRS KLRS Net Change in Cash

Net Change in Cash at other companies

Eli Lilly logo
Eli LillyLLY
-$1.99B-1,035%
Merck & Co. logo
Merck & Co.MRK
-$9.29B-103%
Amgen logo
AmgenAMGN
$2.91B+192%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
-$153.1M-125%
EyePoint, Inc.
 logo
EyePoint, Inc. EYPT
-$24.11M-65.7%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
-$70.36M-65.9%

Other financials

Income statement

See full
Operating income-$11.8M-14.3%
Net income-$10.9M-6.5%
EPS (diluted)-$0.46+81.7%

Balance sheet

See full
Cash & equivalents$34.4M-65.9%
Total debt$1.4M
Total equity$68.6M+7.3%
Total assets$109.8M+6.5%

Cash flow

See full
Operating cash flow-$11.6M-55.6%
CapEx$17.0K
Free cash flow-$7.1M

Valuation

See full
Market cap$96.83M+136%
Enterprise value$63.82M

Returns & leverage

See full
Return on equity-66.6%
Debt / equity
Current ratio12.2×-2.1×

Where this comes from

Reported directly by KLRS in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.

The official record: KLRS’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about KLRS's net change in cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is KLRS's net change in cash?
KLRS (KLRS) reported net change in cash of -$63.63M in Q1 2026.
How has KLRS's net change in cash changed year-over-year?
KLRS's net change in cash decreased by 163.7% year-over-year, from $99.83M to -$63.63M.
What is the long-term trend for KLRS's net change in cash?
Over 2 years (2021 to 2024), KLRS's net change in cash has grown at a -86.2% compound annual growth rate (CAGR), from $79.85M to -$1.53M.
What does net change in cash mean?
Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.